TWST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Twist Bioscience Corp (TWST) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows positive growth trends in revenue and gross margin, the recent insider selling, negative pre-market price movement, and lack of strong proprietary trading signals suggest caution. Holding the stock or waiting for a better entry point may be more prudent.
The technical indicators are mixed. The MACD is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 46.757, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 46.803, with resistance at 55.849. The pre-market price of $47.51 is close to the support level, indicating potential downside risk.
Analysts have raised price targets significantly, with most maintaining Outperform or Buy ratings.
Revenue growth of 16.89% YoY and gross margin improvement to 52.05% indicate operational strength.
The company is positioned to benefit from AI-driven drug discovery and NGS normalization.
Insider selling by the Senior VP, reducing her stake by 24%, has raised concerns among investors.
Hedge funds have significantly increased selling activity, up 634.68% in the last quarter.
The stock is down 2.46% pre-market, reflecting negative sentiment.
Net income and EPS have declined YoY, indicating profitability challenges.
In Q1 2026, revenue increased by 16.89% YoY to $103.7M, and gross margin improved by 7.79% to 52.05%. However, net income dropped by 3.44% YoY to -$30.5M, and EPS fell by 5.66% to -0.5, highlighting ongoing losses.
Analysts are bullish, with multiple firms raising price targets to $50-$52 and maintaining Outperform or Buy ratings. The optimism is driven by the company's positioning in AI-driven drug discovery and NGS markets, as well as its raised 2026 revenue guidance.
